Evaluation of the Effectiveness of Patient Therapeutic Education on Chronic Insomnia
ETP-INSOMNIE
Etude Pilote d'évaluation de l'efficacité de l'ETP Sur l'Insomnie Chronique
1 other identifier
interventional
44
1 country
1
Brief Summary
20 to 30% of the general population suffers from chronic insomnia. Cognitive behavioral therapy (CBT) is the first-line treatment, but unfortunately its implementation is complex. Long waiting times for a consultation / exploration, too short a consultation period, non-reimbursement of specialists and a lack of trained staff make the current care of insomniac patients difficult. Patients are thus treated late, often with heavy drug treatment, dependence on sleeping pills, difficult withdrawal and / or reactive mood disorders. The treatment is therefore limited to advice on sleep hygiene and a restriction of time spent in bed without ultimately intervening in the cognitive domain. Therapeutic education consists of empowering the patient in the management of chronic insomnia through group education workshops. The patient learns the principles of normal sleep, the way in which sleep evolves with aging, the dangers of treatments as well as the rules of sleep hygiene and the behaviors to modify to sleep well. In addition to benefiting from sharing of experience with other patients, therapeutic education makes the care pathway smoother and considerably reduces the long waiting times of the traditional care pathway in consultation. The study investigators hypothesize that therapeutic education is more effective as a treatment for chronic insomnia than traditional management in individualized consultation (IC). Thus, therapeutic education could constitute an effective alternative to CBT.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2022
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 22, 2021
CompletedFirst Posted
Study publicly available on registry
August 11, 2021
CompletedStudy Start
First participant enrolled
September 30, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 29, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
September 29, 2025
CompletedDecember 18, 2024
December 1, 2024
2 years
July 22, 2021
December 13, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Improvement in chronic insomnia between groups
Change in Insomnia Severity Index (ISI) score (Score between 0 - 28) from inclusion
Day 28
Secondary Outcomes (20)
Change in total sleeping time between groups
Day 28
Change in time in bed between groups
Day 28
Change in effective sleep
Day 28
Change in sleep latency
Day 28
Change in intra-sleep time
Day 28
- +15 more secondary outcomes
Study Arms (2)
Therapeutic education
EXPERIMENTALIndividualized consultation
ACTIVE COMPARATORInterventions
In groups of 5-6, patients will have a one-day therapeutic training session comprising 4 workshops: how to create a sleep agenda; normal sleep; sleep hygiene; medical treatments.
once from inclusion for 2 weeks, second for 2 weeks starting 2 weeks after intervention
Eligibility Criteria
You may qualify if:
- The patient must have given their free and informed consent
- The patient must be a member or beneficiary of a health insurance plan
- Patient must understand and read French
- Patient with ICSD-3 diagnostic criteria for chronic insomnia: ISI score \> 14/28.
You may not qualify if:
- Patient with cognitive impairment as assessed by the investigator
- Patient with shift work
- Patients scoring \> 10/24 on the Epworth sleepiness scale
- Patient suffering from medical or psychiatric illnesses which may, in the opinion of the investigator, compromise the subject's state of health or ability to participate in the study.
- Patient with chronic alcohol consumption or drug abuse
- Patient unable to express consent.
- Pregnant, parturient or breastfeeding patient.
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU de NIMES
Nîmes, 30029, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Beatriz Abril
Centre Hospitalier Universitaire de Nīmes
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 22, 2021
First Posted
August 11, 2021
Study Start
September 30, 2022
Primary Completion
September 29, 2024
Study Completion
September 29, 2025
Last Updated
December 18, 2024
Record last verified: 2024-12